Mantle cell lymphoma physical examination: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
{{Mantle cell lymphoma }} | {{Mantle cell lymphoma }} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Akram}} {{AS}} | ||
==Overview== | ==Overview== | ||
Common physical examination findings of mantle cell lymphoma include [[fever]], [[rash]], [[splenomegaly]], [[hepatomegaly]], [[Lymphadenopathy|peripheral lymphadenopathy]], and [[Lymphadenopathy|central lymphadenopathy]]. | Common physical examination findings of mantle cell lymphoma include [[fever]], [[rash]], [[splenomegaly]], [[hepatomegaly]], [[Lymphadenopathy|peripheral lymphadenopathy]], and [[Lymphadenopathy|central lymphadenopathy]]. | ||
Revision as of 02:56, 14 December 2018
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma physical examination On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma physical examination |
|
Risk calculators and risk factors for Mantle cell lymphoma physical examination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2] Sowminya Arikapudi, M.B,B.S. [3]
Overview
Common physical examination findings of mantle cell lymphoma include fever, rash, splenomegaly, hepatomegaly, peripheral lymphadenopathy, and central lymphadenopathy.
Physical Examination
Temperature
Skin
Neck
Thorax
- Thoracic masses suggestive of central lymphadenopathy[4]
- Chest tenderness
Abdomen
- Abdominal masses suggestive of central lymphadenopathy
- Splenomegaly[5]
- Hepatomegaly
- Abdominal tenderness
Extremities
- Peripheral lymphadenopathy[6]
- Bone tenderness[7]
References
- ↑ Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh (2016). "Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents". Oncotarget. 7 (30): 48692–48731. doi:10.18632/oncotarget.8961. PMID 27119356. Unknown parameter
|month=ignored (help) - ↑ A. Pawarode, M. R. Baer, S. Padmanabhan, P. K. Wallace, M. Barcos, S. N. J. Sait, A. W. Block, M. Wetzler & M. Battiwalla (2005). "Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature". Leukemia & lymphoma. 46 (12): 1813–1818. doi:10.1080/10428190500244258. PMID 16263586. Unknown parameter
|month=ignored (help) - ↑ Julie M. Vose (2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". American journal of hematology. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667. Unknown parameter
|month=ignored (help) - ↑ Julie M. Vose (2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". American journal of hematology. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667. Unknown parameter
|month=ignored (help) - ↑ S. Pittaluga, G. Verhoef, A. Criel, I. Wlodarska, J. Dierlamm, C. Mecucci, H. Van den Berghe & C. De Wolf-Peeters (1996). ""Small" B-cell non-Hodgkin's lymphomas with splenomegaly at presentation are either mantle cell lymphoma or marginal zone cell lymphoma. A study based on histology, cytology, immunohistochemistry, and cytogenetic analysis". The American journal of surgical pathology. 20 (2): 211–223. PMID 8554111. Unknown parameter
|month=ignored (help) - ↑ Julie M. Vose (2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". American journal of hematology. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667. Unknown parameter
|month=ignored (help) - ↑ Peng Yang, Jun Lin, Hao Liu, Hao Shen & Hui-Lin Yang (2017). "Primary bone mantle cell lymphomas with multiple vertebral compression fractures: A case report". Oncology letters. 13 (3): 1288–1292. doi:10.3892/ol.2017.5553. PMID 28454248. Unknown parameter
|month=ignored (help)